WELCOME TO THE CELLTRION CONNECT® PATIENT SUPPORT PROGRAM FOR ZYMFENTRA™ (infliximab-dyyb)



Your healthcare provider has prescribed you ZYMFENTRA, and you have been enrolled in the Celltrion CONNECT Patient Support Program for ZYMFENTRA.

YOUR ACTION IS REQUIRED TO PROCESS YOUR ENROLLMENT

Follow these TWO steps:



SIGN THE ENROLLMENT FORM

Your enrollment CANNOT be processed until you sign the enrollment form.



SPEAK WITH YOUR CASE COORDINATOR

You will **receive a call** from your Celltrion CONNECT Case Coordinator from the following phone number:



877-812-6662

When you see this number calling, **please answer the phone** or promptly return our call so that your enrollment can be processed.



You can scan here to download the contact information to your device so you will know it is your Case Coordinator calling.



If you have not signed the enrollment form, please scan above or go to: CelltrionConnect.com/ZYMFENTRA

Please see Medication Guide, including Boxed Warning, by scanning QR code on reverse.

The Celltrion CONNECT Patient Support Program for ZYMFENTRA™ (infliximab-dyyb) provides:

- A dedicated Case Coordinator to help you navigate the enrollment process
- · Information on how your insurance covers ZYMFENTRA and what it will cost you
- Access to Celltrion CONNECT programs to help you pay for ZYMFENTRA, if eligible
- Nurse Connector[™] support to help you transition from intravenous (IV) infliximab to ZYMFENTRA and to
 provide guidance on how to administer it

If you have commercial insurance and experience delays in coverage of ZYMFENTRA, Celltrion may provide ZYMFENTRA at no cost to you.*



If you have any questions about getting started on ZYMFENTRA, please call Celltrion CONNECT at 1-877-81CONNC (1-877-812-6662) from 8 AM – 8 PM EST, Monday – Friday.



Please see Medication Guide, including Boxed Warning, by scanning QR code.

*Celltrion may provide ZYMFENTRA to eligible patients, including those with commercial insurance experiencing delays or a gap in coverage of ZYMFENTRA. Eligible patients must have been prescribed ZYMFENTRA for an FDA-approved indication, and their participation is in no way contingent on any requirement or obligation to purchase ZYMFENTRA or any other Celltrion product or service at any time. Patients who are covered, in whole or part, through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs, or Department of Defense are not eligible to rotinued participation will be verified periodically, and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria, including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan. This offering will end on December 31, 2024. Void where prohibited or restricted by law, and Celltrion reserves the right to rescind, revoke, or amend the terms and conditions at any time without notice.

Celltrion CONNECT® is a registered trademark of Celltrion Holdings, Ltd., used under license. ZYMFENTRA™ is a trademark of Celltrion, Inc., used under license. © Celltrion USA, Inc. 2024 US-ZYM-24-00043 02/24

